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influence reimbursement at national/regional level were interviewed. Results: 
Interviewed EU5 payers emphasize that there are high administrative costs involved 
with providing opioid substitution products to addicted patients, especially for metha-
done, which generally requires daily clinic visits to allow patients to receive their 
medication under direct supervision. A substitution therapy requiring less-frequent 
clinic visits would decrease administrative costs and could be preferred as long as 
efficacy parameters relative to standard-of-care are maintained. Similarly, surveyed 
EU5 physicians indicate that potential for abuse or diversion and patient compliance 
are major considerations for prescribing a new therapy (15% [Spain] to 24% [France] 
and 28% [UK] and 52% [Spain] of respondents cite these factors, respectively, as a 
top three consideration). The former could be decreased and the latter increased if 
therapies were dosed less frequently. A long-acting buprenorphine injection, such 
as Camurus/Braeburn Pharmaceuticals’ CAM-2038, could, therefore, appeal to both 
payers and prescribers. Indeed, 86-96% of surveyed physicians are willing to prescribe 
CAM-2038 if it establishes a similar efficacy, safety, and tolerability profile to exist-
ing buprenorphine products in clinical trials. ConClusions: The opioid addiction 
market is dominated by generic products. However, while payers and prescribers are 
constrained by tight healthcare budgets, our primary research indicates that new 
brands such as long-acting depot CAM-2038 could gain traction via powerful market-
ing that focuses on their ability to reduce potential for abuse/diversion and increase 
compliance, provided existing efficacy and safety standards are maintained.
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objeCtives: Nalmefene (Lundbeck’s Selincro) is the only marketed drug that 
aims to reduce alcohol consumption rather than maintain abstinence in alcohol-
dependent patients. By examining reimbursement and uptake of nalmefene in the 
EU5, we explore market access challenges for the novel treatment pathway this 
drug represents. Methods: In February 2015, 253 psychiatrists in France, Germany, 
Italy, Spain, and the UK were surveyed regarding their prescribing of nalmefene. In 
addition, 15 EU5 payers involved in determining and regulating access to alcohol 
addiction pharmaceuticals were interviewed. Results: On average, 10% (UK) to 
30% (France) of surveyed physicians’ drug-treated alcohol-addicted patients receive 
nalmefene. The most commonly cited reasons for not prescribing nalmefene are 
unfamiliarity with the drug (especially in the UK), a belief that the treatment goal 
should be abstinence, and preference for another pharmacotherapy. Furthermore, 
20% of all surveyed EU5 psychiatrists cite maintaining abstinence/reducing relapse 
as the greatest unmet need in the pharmacological treatment of alcohol addiction, 
while 18% (UK) to 38% (France) identify efficacy for maintaining complete abstinence 
from alcohol after withdrawal and detoxification as their key driver for prescribing 
a new therapy. Interviewed payers similarly consider nalmefene’s goal of reducing 
alcohol consumption rather than maintaining abstinence to be a reimbursement 
challenge, and one that, alongside perceived modest efficacy, has contributed to 
suboptimal HTA ratings in France and Germany, and to total lack of reimbursement 
in Italy. ConClusions: Perception of abstinence as the main aim of treatment 
for alcohol addiction is a considerable market access hurdle for nalmefene and 
emerging alcohol consumption-reducing agents. Robust superiority over compara-
tors, persuasive marketing that illustrates the benefits of alcohol reduction versus 
abstinence, and effective targeting of national, regional and local stakeholders are 
essential to encourage payers to think beyond the price tag, and to maximize famili-
arity with and use of this novel treatment pathway among prescribers.
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objeCtives: To assess the differences in the utilization of drugs indicated for AD 
treatment across different geographic areas in Turkey and to identify the factors 
that may influence possible disparity in the usage. Methods: Summary data for 
all 81 cities in Turkey have been collected. The data include IMS sales (standard 
unit sales data of all products indicated for AD -memantin, rivastigmin, donepezil, 
galantamin), demographic (age distribution, education level, population density 
etc.), health policy (number of family physicians and specialists, hospital beds, nurs-
ing houses, average hospital admission rate) and affordability data (social security 
coverage rate). We calculated “utilization score” for all cities, dividing the number 
of standard units sold by the number of subjects who are assumed to have AD. A 
composite “indicator score” was calculated for all cities, summing the weighted val-
ues of all indicators. The relationship of the indicators and the composite indicator 
scores with “utilization score” were analyzed by means of Pearson and Spearman 
correlation analysis as needed. Then, a multivariate regression model was built to 
determine the degree of impact of each indicator. Results: There were significant 
differences in the relative utilization of AD treatments among cities and regions. 
Generally industrialized and larger cities had higher utilization than smaller and/
or less-developed cities by means of infrastructure. It is seen from the multivariate 
regression model that, utilization Index increases when SGK coverage rate and 
population density increase and when household size decrease. ConClusions: 
Geographical disparities in the usage are initially assumed to be related to scarci-
ties in healthcare infrastructure and regional socio-economic factors. However, it is 
seen that healthcare infrastructure is less influential on utilization disparity, which 
has found to be highly driven by socio-economics factors including affordability, 
population density (disperse residence) and household size (indirect indicator for 
socio-economy and family member to provide caregiver service in Turkish culture)
patients and one of caregivers. ConClusions: Most study abstracts reporting 
on the humanistic burden in dementia in 2014 did not specify use of a dementia-
specific instrument. Only 25% of studies assessed burden on caregivers, and utility 
values were rarely reported.
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objeCtives: To evaluate the association between caregiver’s reported attention-
deficit/hyperactivity disorder (ADHD) medication satisfaction (MS) and child and 
caregiver socio-demographics; ADHD severity; comorbidities; medication attributes; 
treatment classes. Methods: CAPPA is a cross-sectional online survey of caregivers 
of children (6–17 years) with ADHD receiving pharmacological treatment for ADHD at 
survey completion (2012–2013) in 10 European countries. ADHD Rating Scale Version 
IV (ADHD-RS-IV) total score during treatment interruption (off medication) was used 
as a proxy for baseline severity. Caregivers were asked to rate satisfaction with medi-
cation attributes (Convenience: administration frequency, tablet size; Effectiveness: 
duration of action, time to onset, symptom control; Safety: side effects, abuse/mis-
use potential, dependence/addiction potential) on a 7-point scale ranging from ‘very 
satisfied’ to ‘very dissatisfied’. Children’s comorbidities at baseline/treatment classes 
were also reported by caregivers. Significant factors (p< 0.01) using bivariate and cor-
relation analyses are reported. Results: Among 3688 respondents, 2853 (77%) whose 
child was using ADHD medication at survey completion were evaluated. Children’s 
mean (SD) age was 11.4 (3.1) years, 81% were male; 67% of caregivers were female. 
MS was rated as: very satisfied (20%), satisfied (39%), moderately satisfied (29%), and 
combined neither satisfied nor dissatisfied, moderately dissatisfied, dissatisfied or 
very dissatisfied (12%). Better MS was reported with lower ADHD severity and fewer 
comorbidities. Comorbidities significantly associated with lower MS were anxiety, 
conduct disorder, aggression and oppositional defiant disorder. Medication attributes 
with strongest correlation to MS were symptom control (r= 0.6), duration of action 
(0.5) and time to onset (0.4). Significantly higher MS was associated with caregivers 
who were married, female, employed or a parent with ADHD. MS varied by coun-
try. ConClusions: Lower ADHD severity and fewer comorbidities were associated 
with higher MS. Effectiveness attributes were of highest priority to caregivers and 
MS differed by caregiver characteristics. These factors should be considered when 
making a treatment plan.
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objeCtives: Mental Health Disorders impair occupational performance and 
lead to handicap and economic deprivation. The current contribution quantifies 
the degree of these problems among two representative samples of the German 
and the UK population. Methods: Two representative samples (n= 3,571) of the 
adult population (20-65 years) in Germany and UK were surveyed in 2012 with 
a questionnaire containing information about occupational status, job related 
handicaps, economic and demographic information. From a survey five years 
earlier (2007) information for the same persons about possible mental health 
disorders and their treatment were available. Longitudinal regression analysis 
estimates the impact of mental status on occupational disability and financial 
deprivation Results: In the initial survey 18.5% of the sample suffered from 
depression and 7.0% from anxiety/ phobia. 53.8% of the depressive individuals 
and 56.8% of the individuals suffering from anxiety or phobia were treated by 
General Practitioners or Specialists. Five years later unemployment due to men-
tal health reasons was reported by 57.2% of the persons with treated mental 
health disorders but only by 19.9% of the group with no mental health disorders. 
Individuals with mental disorders needed – among other handicaps - more often 
breaks at work than persons with no disorders (33.3% vs. 8.5%) or could no longer 
perform all elements of their jobs (28.9% vs. 6.9%). Occupational handicap resulted 
in economic deprivation: 28.0% of the treated mental health group reported a 
monthly net income of less than 800GP compared to 13.2% of the group with no 
mental health disorders. ConClusions: Mental Health Disorders have consider-
able impacts on occupational performance, participation in work life and on the 
financial economic situation. Individuals who are under treatment suffer more 
often from these handicaps than untreated - presumably because of their more 
severe disease status.
Mental HealtH – Health care use & Policy studies
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objeCtives: Standard-of-care for opioid addiction is substitution therapy with 
methadone, buprenorphine, or buprenorphine/naloxone. As EU5 healthcare budgets 
tighten, this study explored how emerging brands may gain a foothold in this increas-
ingly generic market, as payers and prescribers balance clinical need with limited 
funds. Methods: In February 2015, 253 EU5 psychiatrists were surveyed regarding 
their prescribing for opioid addiction. In addition, 15 payers/payer-advising KOLs who 
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were not significantly different on MDD-related outpatient services (least-squares 
mean difference[95% CI] for number of outpatient visits: 0.31[-0.01, 0.64]; OR[95% 
CI] for having ≥ 2 outpatient visits: 1.04[0.82, 1.32] for SNRI vs SSRI). ConClusions: 
Chinese physicians seem more likely to choose SNRI than SSRI for the treatment of 
severely-ill MDD patients, as suggested by the patients’ higher likelihood of being 
treated at mental hospitals and having more MDD-related outpatient visits pre-
medication initiation. Although SNRI initiators may be more severely-ill at medica-
tion initiation, they were not found to differ from SSRI initiators on outpatient and 
inpatient service use for MDD in the year following medication initiation.
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objeCtives: Antidepressants use is increasing worldwide but is particularly high 
in Belgium compared to other EU countries whereas suicide-rates in Belgium are 
among the highest. This could reflect misuse of antidepressants resulting in an 
important economic burden. The latter is part of a separate abstract. This study 
assesses the prescribing patterns of antidepressants in Belgium and whether there 
is misuse or not. Methods: Given the efforts to deinstitutionalize mental health 
services, primary care plays now an important role in the diagnosis and treatment 
of mild to moderate mental health disorders. As such, patients treated in 2014 that 
had no prescription with antidepressants in 2013 were analysed from the IMS Health 
Longitudinal Patients Database (IMS Health LPD). The reasons for antidepressant 
prescription and the treatment duration were assessed. The IMS Health LPD, in 
Belgium collects information on diagnosis and prescriptions of a set of 360 general 
practitioners covering about 300,000 patients. Data is collected through an office-
based Electronic Medical Records software. Results: IMS Health LPD showed that 
60% of patients taking antidepressants receive it for depression. The next most 
frequent diagnosis was sleeping disorders (17%) and anxiety (7.5%). Moreover, of 
the patients with depression, 16% received only 1 prescription of an antidepressant 
covering at maximum a month of treatment. This can be considered insufficient 
given the mode of action of these drugs (treatment effect only starts after three 
weeks). ConClusions: Real world data on Belgian antidepressants prescription 
clearly shows that antidepressants are used outside the generally accepted indica-
tions and, when used in the correct indication for a too short time period. By improv-
ing prescribing patterns of antidepressants mental health indicators might improve.
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objeCtives: Antidepressants use is increasing worldwide but is particularly high 
in Belgium compared to other EU countries whereas suicide-rates in Belgium are 
among the highest. This could reflect misuse of antidepressants resulting in an 
important economic burden. The former is part of a separate abstract. The aim 
here was to evaluate potential savings that could be realized in case prescrip-
tions behavior in Belgium would be similar to neighbor countries. Methods: 
Current spending levels for antidepressants and mood stabilizer prescriptions 
were determined in Belgium, France and the Netherlands. Volume and value sales 
were determined per country (average number of pills sold/capita) based on IMS 
Health Belgian National Retail Database available to IMS Health in both countries 
via the IMS MIDAS platform (2013 data). The potential country-level prescription 
cost in Belgium was estimated by multiplying average number of pills/person 
in France and the Netherlands, with the cost/pill in Belgium and extrapolating 
the result to the total population in Belgium, assuming that prescribing levels in 
Belgium were equal to those in France and the Netherlands and using Belgian 
prices. Results: In Belgium the number of pills per capita is respectively 45% 
and 48% higher compared to France and the Netherlands (34.17 vs. 23.62 vs. 23.15 
pills/person). With a 30% smaller population than the Netherlands, spending in 
Belgium is 4 times higher. In France, having a 6 times larger population compared 
to Belgium, spending is only 3 times higher. The estimated savings for the Belgian 
payer applying the usage (pill/person) of respectively France and the Netherlands 
and current cost/pill in Belgium were € 67 and € 70 Mn, meaning around 30% of 
current spending in Belgium. ConClusions: By comparing Belgium’s prescrip-
tion patterns to France and the Netherlands, we estimated important potential 
savings due to antidepressant mis-use/over-use that could be re-invested in for 
example mental health prevention.
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objeCtives: Depression is the most common psychiatric disease in the world that 
has a reactive environmental character, where the atmosphere can provide this 
disease. The objective of this study was to identify the types of drug treatments 
for depression, in 2014, with data from the health insurance of Brazil. Methods: 
The patients were identified through the health insurance database of Brazil, 
from January to December 2014, who bought some antidepressants medication 
in the analyzed period. From the date of the purchase, it was possible to obtain 
a methodology capable of identifying the age of these patients and the main 
molecules used for the treatment. Results: From a total of 884.143 patients who 
used any type of antidepressant, it was found that 85 % of these patients used the 
following molecules: Fluoxetine (19.0%), Sertraline (18.6%), Escitalopram (14.1%), 
Paroxetine (12.8 %), Bupropion (11.1%) and Amitriptyline (9.5%). Considering the 
age of these patients it was identified that from the age of 30, the incidence in the 
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objeCtives: The objective of the study is to provide utilization data for lisdexam-
fetamine dimesylate (LDX) following its launch in 2013 in Europe for treatment of 
attention deficit hyperactivity disease (ADHD). Methods: This is a multi-country 
drug utilization study using database analysis. Longitudinal EMR databases (Disease 
Analyzer, Germany and CPRD, United Kingdom), National Registries (Denmark, 
Sweden), prescription databases using pharmacy retail data (IFAK/New Index, 
Switzerland) and cross-sectional databases (Prescribing Insights Spain, Switzerland) 
were used. The study includes all patients in the databases who have been pre-
scribed LDX at least once during the study period (March [first EU launch] 2013 – 
December 2014). Results: The majority of patients treated with LDX were males 
in all six European countries studied: Germany (84% in Paediatrician Panel, 78% in 
Neurology/Psychiatry panel), UK (82%), Spain (87%), Denmark (63%), Sweden (60%) 
and Switzerland (75%). Less than 1% of all patients were < 6 years in all countries 
studied. The proportion of patients treated with LDX > 18 years of age was estimated 
to be 12% in Germany (Neurology/Psychiatry Panel Germany), 12% in the UK (CPRD), 
45% in Denmark, 60% in Sweden and 70% in Switzerland. Prescribed average daily 
dose (ADD) of LDX was within the recommended range (30-70mg) for 97% to 100% of 
the patients, with a mean ADD of 44mg in Germany, 48mg in UK and about 44mg in 
Sweden. In Denmark and Switzerland, the recommended dose was not recorded on 
the prescription. ConClusions: Overall, the findings indicate that LDX is mainly 
prescribed within the EMA-approved Summary of Product Characteristics with 
regard to the indicated patients and dose regimen. Adult use is more common in 
Switzerland where use of LDX was already licensed for adults in 2014, or in Denmark 
and Sweden where use of LDX is indicated for adults as of 2015. Prescribed use in 
patients less than 6 years is ≤ 1%.
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objeCtives: A subset of patients with Major Depressive Disorder (MDD) who are 
treated with, but do not respond to antidepressant and/or antipsychotic (ADAP) 
drugs/ mood stabilizers are characterized as progressing to treatment resistant 
depression (TRD). This study characterized TRD and non-TRD episodes among 
MDD patients in the UK Clinical Practice Research Datalink (CPRD) during 2000-
2012. Methods: Business rules centered on diagnosis and use of antidepressants 
were used to identify new MDD episodes. Treatment regimens were defined as 
mono- or combination therapy with concurrently administered ADAP drugs. TRD 
was defined as ≥ 2 distinct failed regimens in an episode. Adults 18 to 65 years of 
age were included. Results: Of the 427,467 MDD patients, 291,388 (68.2%) were 
excluded because they lacked an index diagnosis date, met an exclusion diagno-
sis criterion, did not meet the age criteria, or had missing age or gender; 136,079 
patients (31.8%) were retained. A total of 6,311 (5.1%) distinct episodes with ≥ 1 ADAP 
prescription were treatment-resistant, with 6,221 (5.9%) of all patients experienc-
ing ≥ 1 TRD episode. Median time to developing TRD was < 11 months (307 days). 
Mean duration of a TRD episode was 1,239 days versus only 305 days for non-TRD 
episodes. Nearly half (46%) of all TRD episodes had up to 4 lines of treatment (LOTs); 
in contrast, only 19% of non-TRD episodes with ≥ 1 ADAP prescription had > 1 LOT. 
Use of combination drug regimens was seen in 46.6% of TRD episodes compared 
with 12.8% of drug-treated non-TRD episodes. TRD episodes were associated with 
higher electroconvulsive therapy exposure, more psychiatrist visits and behavioral 
therapy sessions versus non-TRD episodes. More TRD patients suffered from co-
morbidities such as anxiety and panic disorder. ConClusions: This analysis of 
data from the largest provider of health care in the UK highlights the significant 
burden of TRD on patients and providers.
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objeCtives: To compare baseline characteristics and major depressive disorder 
(MDD)-related healthcare resource use during the 1-year post-medication initia-
tion of patients with MDD who were initiated on selective-noradrenaline-reup-
take inhibitor (SNRI) compared to selective-serotonin-reuptake inhibitor (SSRI) in 
Beijing. Methods: Data from the Beijing Urban Employee Basic Medical Insurance 
Database from July 1, 2011-December 31, 2013, were used. Patients diagnosed with 
MDD were identified using ICD-10th F32/F33. The first-diagnosis date in 2012 was 
designated as the index date. Patients were aged ≥ 18 years; without comorbid can-
cer, schizophrenia, or bipolar disorder; and with 12-months continuous enrollment. 
Logistic regression with stepwise-effect-selection method and multivariate analy-
ses were performed. Results: A total of 4769 patients were included, with 8.6% 
initiated on SNRI. Compared with SSRI initiators, SNRI initiators were more likely 
to be treated at mental than general hospitals (Odds ratio (OR) [95% confidence 
interval (CI)]: 1.96[1.58, 2.42]), had more MDD-related outpatient visits during the 
6-month pre-index date (1.18[1.11, 1.25]), and were more likely to be treated at 
tier-3 hospitals (0.15[0.06, 0.41] for tier 1 vs 3; 0.50[0.36, 0.69] for tier 2 vs 3). In the 
year following medication initiation, few patients (0.5%) experienced MDD-related 
hospitalizations in either medication initiation group. The SNRI and SSRI initiators 
